Next Big Tech Trend Will Put Well Known Businesses in Bankruptcy
Legend who bought Amazon at $48 says there’s a huge new tech trend coming to your hometown – which could make you a small fortune over the next few years. And today he’s revealing the name and stock ticker symbol of his favorite way to make money from this trend.
See it FREE right here.
pixel

PHAS Insider Trading (PhaseBio Pharmaceuticals)

Insider Ownership Percentage: 17.00%
Insider Buying (Last 12 Months): $42,720.00
Insider Selling (Last 12 Months): $12,064.65

PhaseBio Pharmaceuticals Insider Trading History Chart

PhaseBio Pharmaceuticals Share Price & Price History

$3.88
▼ -0.01 (-0.26%)
As of 02/26/2021 01:00 AM ET
Days: 30 | 90 | 365
Man Gets Into a Tesla… What Happens Next Will Shock Everyone (Video)
"Hi, I'm Jeff Brown… I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project…

What happens next will shock you…"
Click here to see what happened.

PhaseBio Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2020Edmund HarriganDirectorBuy6,000$4.12$24,720.006,000  
11/24/2020Clay ThorpDirectorBuy5,000$3.60$18,000.00
11/23/2020Glen BurkhardtVPSell3,497$3.45$12,064.653,497  
7/1/2019Clay ThorpDirectorSell2,908$14.00$40,712.00  
6/18/2019Clay ThorpDirectorSell400$14.00$5,600.00  
12/17/2018Nancy J HutsonDirectorBuy1,000$4.46$4,460.00  
12/13/2018Jonathan P MowCEOBuy1,000$3.69$3,690.00  
12/11/2018Michael YorkVPBuy1,500$3.88$5,820.00  
12/10/2018Jonathan P MowCEOBuy3,000$3.87$11,610.00  
12/7/2018John P SharpCFOBuy5,000$3.84$19,200.00  
12/4/2018Clay ThorpDirectorBuy4,000$3.13$12,520.00  
10/22/2018Linda TuftsDirectorBuy20,000$5.00$100,000.00  
10/22/2018Venture Advisors Iii HatterasMajor ShareholderBuy300,000$5.00$1,500,000.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for PhaseBio Pharmaceuticals (NASDAQ:PHAS)

58.58% of PhaseBio Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

PhaseBio Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/24/2021Virtu Financial LLC28,821$97K0.0%N/A0.098%
2/19/2021JPMorgan Chase & Co.41,006$0.14M0.0%+616.6%0.140%
2/16/2021ETF Managers Group LLC14,283$50K0.0%-13.1%0.049%
2/12/2021Stifel Financial Corp210,125$0.71M0.0%+11.9%0.716%
2/10/2021Rhumbline Advisers10,492$35K0.0%N/A0.036%
2/10/2021Renaissance Technologies LLC83,400$0.28M0.0%N/A0.284%
2/9/2021Wells Fargo & Company MN24,792$83K0.0%+17.8%0.084%
2/9/2021Bank of New York Mellon Corp36,965$0.13M0.0%-7.0%0.126%
2/9/2021Blair William & Co. IL67,500$0.23M0.0%N/A0.230%
2/5/2021BlackRock Inc.1,193,607$4.01M0.0%+5.2%4.065%
2/4/2021GSA Capital Partners LLP140,341$0.47M0.1%-9.1%0.478%
11/30/2020Platform Technology Partners92,950$0.33M0.2%+72.2%0.317%
11/13/2020Morgan Stanley101,650$0.36M0.0%-37.1%0.346%
11/10/2020State Street Corp300,757$1.06M0.0%+16.5%1.025%
11/6/2020BlackRock Inc.1,134,939$3.98M0.0%+4.9%3.868%
11/6/2020GSA Capital Partners LLP154,316$0.54M0.1%N/A0.526%
8/31/2020Bridgeway Capital Management Inc.152,600$0.70M0.0%-16.8%0.520%
8/25/2020Nuveen Asset Management LLC32,355$0.15M0.0%-23.9%0.110%
8/20/2020Charles Schwab Investment Management Inc.40,648$0.19M0.0%+10.5%0.139%
8/14/2020Bank of America Corp DE7,171$33K0.0%+73.5%0.025%
8/14/2020Sabby Management LLC76,970$0.35M0.1%-28.5%0.267%
8/12/2020Goldman Sachs Group Inc.28,517$0.13M0.0%-41.0%0.099%
8/3/2020Leap Investments LP15,800$73K0.0%N/A0.055%
7/22/2020First Trust Advisors LP30,008$0.14M0.0%+7.7%0.104%
7/16/2020Wedbush Securities Inc.11,400$52K0.0%N/A0.040%
6/19/2020State Street Corp249,310$0.83M0.0%+8.5%0.866%
5/15/2020Sabby Management LLC107,577$0.36M0.1%+14.0%0.374%
5/15/2020Morgan Stanley85,623$0.28M0.0%-16.5%0.297%
5/15/2020DAFNA Capital Management LLC320,542$1.06M0.4%-11.1%1.114%
5/15/2020Ghost Tree Capital LLC497,074$1.65M0.4%+10.5%1.727%
5/14/2020Wells Fargo & Company MN16,832$55K0.0%+107.0%0.058%
5/14/2020Geode Capital Management LLC214,659$0.71M0.0%+13.1%0.746%
5/14/2020Wellington Management Group LLP4,027,284$13.33M0.0%+3.5%13.993%
5/14/2020Nuveen Asset Management LLC42,501$0.14M0.0%+14.8%0.148%
5/11/2020State Street Corp249,310$0.83M0.0%+8.5%0.866%
5/6/2020First Trust Advisors LP27,875$92K0.0%-16.2%0.097%
5/6/2020Bank of New York Mellon Corp41,251$0.14M0.0%+16.1%0.143%
5/1/2020BlackRock Inc.989,790$3.28M0.0%-1.0%3.439%
5/1/2020UBS Group AG9,863$33K0.0%-45.4%0.034%
2/20/2020Geode Capital Management LLC189,717$1.16M0.0%+4.0%0.659%
2/14/2020Goldman Sachs Group Inc.116,413$0.71M0.0%+6.0%0.405%
2/14/2020UBS Group AG18,059$0.11M0.0%+39.8%0.063%
2/13/2020Parkman Healthcare Partners LLC91,091$0.56M0.2%N/A0.317%
2/13/2020Farallon Capital Management LLC1,000,000$6.11M0.0%+23.8%3.476%
2/13/2020Stifel Financial Corp163,043$0.98M0.0%-19.9%0.567%
2/12/2020Sectoral Asset Management Inc178,000$1.09M0.2%-9.2%0.619%
2/11/2020TD Asset Management Inc.43,843$0.27M0.0%+11.4%0.152%
2/11/2020Quantitative Systematic Strategies LLC10,947$67K0.0%N/A0.038%
2/10/2020Barclays PLC21,969$0.13M0.0%+41.1%0.076%
2/6/2020Acadian Asset Management LLC13,799$84K0.0%+179.4%0.048%
2/6/2020State Street Corp229,779$1.40M0.0%+3.9%0.799%
2/4/2020Virtu Financial LLC13,422$82K0.0%N/A0.047%
1/10/2020FNY Investment Advisers LLC10,000$61K0.0%N/A0.035%
11/27/2019Millennium Management LLC60,146$0.25M0.0%N/A0.209%
11/27/2019Sabby Management LLC124,788$0.52M0.3%+50.5%0.434%
11/27/2019Barclays PLC15,566$65K0.0%-40.7%0.054%
11/27/2019Stifel Financial Corp203,458$0.84M0.0%+178.9%0.707%
11/27/2019State Street Corp221,242$0.92M0.0%+16.6%0.769%
11/4/2019Alps Advisors Inc.55,856$0.23M0.0%-5.0%0.195%
11/4/2019First Trust Advisors LP33,855$0.14M0.0%N/A0.118%
9/11/2019River & Mercantile Asset Management LLP20,000$0.26M0.0%N/A0.070%
8/16/2019United Services Automobile Association107,267$1.41M0.0%+15.8%0.438%
8/15/2019River & Mercantile Asset Management LLP20,000$0.26M0.0%N/A0.070%
8/15/2019Price T Rowe Associates Inc. MD796,236$10.45M0.0%+22.2%3.250%
8/14/2019Morgan Stanley84,194$1.10M0.0%+3,673.8%0.344%
8/14/2019Cormorant Asset Management LP906,229$11.89M0.7%+7.9%3.699%
8/14/2019Vanguard Group Inc.673,620$8.84M0.0%+266.1%2.750%
8/14/2019Farallon Capital Management LLC756,961$9.93M0.1%N/A3.090%
8/14/2019Rock Springs Capital Management LP1,423,256$18.67M0.7%+24.8%5.810%
8/13/2019BlackRock Inc.895,427$11.75M0.0%+1,878.4%3.655%
8/13/2019Virtus ETF Advisers LLC22,949$0.30M0.1%N/A0.094%
8/13/2019Northern Trust Corp37,027$0.49M0.0%N/A0.151%
8/12/2019Bank of New York Mellon Corp38,169$0.50M0.0%N/A0.156%
8/10/2019Charles Schwab Investment Management Inc.36,799$0.48M0.0%N/A0.150%
8/7/2019Alps Advisors Inc.58,775$0.77M0.0%N/A0.240%
8/7/2019NEA Management Company LLC6,643,704$87.17M6.1%N/A27.117%
8/7/2019JPMorgan Chase & Co.3,769$48K0.0%N/A0.015%
8/6/2019Wells Fargo & Company MN16,046$0.21M0.0%N/A0.065%
8/1/2019TD Asset Management Inc.40,343$0.53M0.0%+26.9%0.165%
6/30/2019Strs Ohio3,700$48K0.0%N/A0.015%
4/4/2019Tibra Equities Europe Ltd22,778$0.22M0.0%N/A0.093%
2/15/2019Millennium Management LLC133,022$0.41M0.0%N/A0.543%
2/13/2019United Services Automobile Association92,614$0.29M0.0%N/A0.378%
2/12/2019Citigroup Inc.113,605$0.35M0.0%N/A0.464%
2/8/2019BlackRock Inc.25,309$79K0.0%N/A0.103%
Data available starting January 2016

See Full Table
PhaseBio Pharmaceuticals logo
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Read More

Today's Range

Now: $3.88
$3.76
$4.02

50 Day Range

MA: $4.28
$3.74
$5.55

52 Week Range

Now: $3.88
$2.60
$6.85

Volume

167,093 shs

Average Volume

347,815 shs

Market Capitalization

$113.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Who are the company insiders with the largest holdings of PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' top insider shareholders include:
  1. Edmund Harrigan (Director)
  2. Glen Burkhardt (VP)
  3. Clay Thorp (Director)

Who are the major institutional investors of PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' top institutional shareholders include:
  1. BlackRock Inc. — 4.06%
  2. Stifel Financial Corp — 0.72%
  3. GSA Capital Partners LLP — 0.48%
  4. Renaissance Technologies LLC — 0.28%
  5. Blair William & Co. IL — 0.23%
  6. JPMorgan Chase & Co. — 0.14%

Which major investors are selling PhaseBio Pharmaceuticals stock?

In the previous quarter, PHAS stock was sold by these institutional investors:
  1. GSA Capital Partners LLP
  2. Bank of New York Mellon Corp
  3. ETF Managers Group LLC

Which major investors are buying PhaseBio Pharmaceuticals stock?

During the last quarter, PHAS stock was purchased by institutional investors including:
  1. Renaissance Technologies LLC
  2. Blair William & Co. IL
  3. BlackRock Inc.
  4. JPMorgan Chase & Co.
  5. Virtu Financial LLC
  6. Stifel Financial Corp
  7. Rhumbline Advisers
  8. Wells Fargo & Company MN
Within the last year, these company insiders have bought PhaseBio Pharmaceuticals stock:
  1. Edmund Harrigan (Director)
  2. Glen Burkhardt (VP)
Elon Musk’s Next BIG Bet
First he bet it all on PayPal and made millions...

Then he bet it all on Tesla and made billions.

Now he’s going all-in again...
And this time he plans to dominate